In support of this notion, we show herein that the catalytic AKT inhibitor AZD5363 inhibited the growth of ER+ human breast cancer cells with acquired resistance to estrogen deprivation and prevented the emergence of hormone-independent cells. The gene discussed is ESR1; the disease is breast cancer.